ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,555.74
-0.16%
US Tech 100
19,166.00
-0.66%
Dow Jones
40,358.09
-0.14%
Brent Oil
80.775
-0.91%
Bitcoin
65,908.09
-2.51%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arcutis Biotherapeutics Inc (ARQT) Quote

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc (ARQT)

NASDAQ
10.20
0.35
(3.55%)
At close: July 23 4:00PM
Delayed by 15 minutes
10.20
0.00
( 0.00% )
After Hours: 4:00PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
10.20
Bid
9.91
Ask
10.33
Volume
1,900,426
9.78 Day's Range 10.31
1.76 52 Week Range 13.17
Market Cap
1.181B
Previous Close
9.85
Open
9.80
Last Trade
15
@
10.2
Last Trade Time
17:04:01
Financial Volume
$ 19,317,258
VWAP
10.1647
Average Volume (3m)
2,969,832
Shares Outstanding
115,764,164
Dividend Yield
-
PE Ratio
-4.50
Earnings Per Share (EPS)
-2.26
Revenue
59.61M
Net Profit
-262.14M

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targe... Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.arcutis.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arcutis Biotherapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARQT. The last closing price for Arcutis Biotherapeutics was $9.85. Over the last year, Arcutis Biotherapeutics shares have traded in a share price range of $ 1.76 to $ 13.17.

Arcutis Biotherapeutics currently has 115,764,164 shares outstanding. The market capitalization of Arcutis Biotherapeutics is $1.14 billion. Arcutis Biotherapeutics has a price to earnings ratio (PE ratio) of -4.50.

ARQT Latest News

More News

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Approximately 40% of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalpOnce-daily ZORYVE foam significantly improved both scalp and body...

10 hours ago
GlobeNewswire Inc.

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

WESTLAKE VILLAGE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful...

July 22 2024
GlobeNewswire Inc.

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatmentZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom...

July 09 2024
GlobeNewswire Inc.

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful...

July 09 2024
GlobeNewswire Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful...

July 03 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.74-6.7641681901310.9411.229.53160769910.1094101CS
41.3615.38461538468.8411.228.5627176719.97554233CS
121.5117.37629459158.6911.226.9929698329.00995867CS
266.61184.1225626743.5913.173.5937637998.89256572CS
52-0.27-2.578796561610.4713.171.7634556656.41592435CS
156-14.77-59.150981177424.9727.41.7615529298.83775623CS
260-12.85-55.74837310223.0540.881.76109949310.02568792CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 1.83
(77.67%)
686.5k
ALLRAllarity Therapeutics Inc
$ 0.285
(71.17%)
38.16M
NIVFNewGenIvf Group Ltd
$ 1.31
(50.42%)
4.08M
SLNASelina Hospitality PLC
$ 0.0313
(20.38%)
40.6M
DRMADermata Therapeutics Inc
$ 1.55
(19.23%)
96.58k
VSTMVerastem Inc
$ 2.73
(-23.96%)
381.66k
IONMAssure Holdings Corporation
$ 1.91
(-21.40%)
43.89k
CJETChijet Motor Company Inc
$ 4.20
(-17.32%)
89.02k
SLRXSalarius Pharmaceuticals Inc
$ 2.19
(-16.09%)
209.77k
ALPPAlpine 4 Holdings Inc
$ 0.513
(-14.49%)
296.92k
SLNASelina Hospitality PLC
$ 0.0313
(20.38%)
40.6M
ALLRAllarity Therapeutics Inc
$ 0.285
(71.17%)
38.16M
TSLATesla Inc
$ 232.00
(-5.84%)
13.71M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.13
(-11.46%)
11.91M
HOLOMicroCloud Hologram Inc
$ 0.5999
(2.58%)
8.78M

ARQT Discussion

View Posts
52172 52172 2 weeks ago
Not yet need 20’s which will come
👍️ 1
MiamiGent MiamiGent 2 weeks ago
ARQT $10.82 HOD!
Everybody happy?
👍️0
52172 52172 2 weeks ago
Some large transactions happening a sign of whats to come
👍️ 1
52172 52172 2 weeks ago
Gonna close green watch
👍️0
MiamiGent MiamiGent 2 weeks ago
ARQT The short interest is about 25%
The free trading float is tiny.
Share Price should rise steadily today.
👍️0
MiamiGent MiamiGent 2 weeks ago
ARQT $10.69 last pre-mkt buy, up .67 from yesterday's close.
Steadily rising, as I expected.

The mkt for this FDA approved medicine (last night) is reportedly multi- billions of dollars.
👍️0
52172 52172 2 weeks ago
Im hoping!
👍️0
MiamiGent MiamiGent 2 weeks ago
ARQT Needham Reiterates BUY on Arcutis Biotherapeutics, maintains $18 Price Target

6:28 AM this morning
👍️0
MiamiGent MiamiGent 2 weeks ago
ARQT That's right. The market for this is reportedly three times larger than the previous approved candidate- and that one grew about 250% last qtr.
AND, Arcutis (ARQT) will roll out this new medicine by the end of THIS MONTH.

I am going to buy this product- I have psoriasis all over, except my face thank God.
👍️0
52172 52172 2 weeks ago
Real revenue is gonna begin to come in.
👍️0
52172 52172 2 weeks ago
Headed to 20’s soon enough!
👍️0
MiamiGent MiamiGent 2 weeks ago
$ARQT HUge short interest, next to no free float and FDA Approval tonight for a BIG MARKET drug.
The boys will run this tomorrow.
👍️0
MiamiGent MiamiGent 2 weeks ago
$ARQT
Arcutis Biotherapeutics Inc

My guess it'll be $11 by 8PM.
The real fun starts in Pre-Market, tomorrow, And then I think off to the races in Regular Session.
Bullish
👍️0
MiamiGent MiamiGent 2 weeks ago
$ARQT Tight Bid and ASK now.
Getting serious.
Bid ARCX
10.55 x 10
Ask XNMS
10.59 x 1
Volume
2,437,578
Bullish
👍️0
MiamiGent MiamiGent 2 weeks ago
$ARQT
Arcutis Biotherapeutics Inc

I told ya!
Currently in AH
Bid XNMS 10.50 x 13
Ask ARCX 10.67 x 20
Volume
2,429,849
Bullish
👍️0
MiamiGent MiamiGent 2 weeks ago
$ARQT New traders: Look at those big $10.48 buys!
The few that follow are "paint jobs"- shorts trying to paint weakness.
Pay attention to the big buys!
$ARQT
18:07:49 $10.41 5 paint job
18:07:49 $10.35 20 paint job
18:07:45 $10.48 15 paint job
18:07:25 $10.48 7,900 real buy
18:07:25 $10.48 1,500 real buy
18:07:01 $10.3567 30
18:05:44 $10.49 115
18:04:57 $10.49 9,400
18:04:26 $10.4887 110
18:03:38 $10.42 6,212
18:03:38 $10.42 2,200
Bullish
👍️0
MiamiGent MiamiGent 2 weeks ago
ARQT Arcutis Biotherapeutics' Zoryve Gets US FDA Approval!
👍️0
Sierra20 Sierra20 2 weeks ago
I hope it will be approved. I think it will be approved. It’s just weird.
👍️0
MiamiGent MiamiGent 2 weeks ago
You're being unnecessarily doomsdayish, Sierra.

Fact is FDA has not announced re any candidates since July 3rd. There's an American holiday on the 4th (Thursday) and folks often take the next day off to make it a four-day break with only one vacation day used.
Hope the weather is not as hot in Albania or wherever it is you plot your short plays and bashing.
MG
👍️0
Sierra20 Sierra20 2 weeks ago
CRL more than likely. I knew it. F! This is horrible!!!!
https://investors.arcutis.com/news-releases/news-release-details/arcutis-provides-update-snda-roflumilast-cream-015-atopic/
👍️0
Sierra20 Sierra20 2 weeks ago
They got CRL. 😔
There’s no other reason for this delay. Back to $5 I think.
👍️0
Sierra20 Sierra20 2 weeks ago
I think they are talking to fda to figure out what they needed to do to address the fda’s concerns before giving a pr about CRL.
👍️0
MiamiGent MiamiGent 2 weeks ago
ARQT Only 40 more minutes for FDA to announce today.
One time it did at 11:30 PM and it was a QUADRUPLE!
👍️0
MiamiGent MiamiGent 2 weeks ago
You must be short. There's no basis for what you are saying.
👍️0
MiamiGent MiamiGent 2 weeks ago
AQRT I'm in today.
👍️0
Sierra20 Sierra20 2 weeks ago
CRL coming at 4 pm est. imo.
👍️0
Sierra20 Sierra20 2 weeks ago
I think CRL coming…
👍️0
Sierra20 Sierra20 2 weeks ago
Run
👍️0
52172 52172 2 weeks ago
Havent missed nothing yet!
👍️0
52172 52172 2 weeks ago
Monday boom!
👍️0
Sierra20 Sierra20 3 weeks ago
I have the worst luck. I miss all the PDUFA. If they get delayed should not be a problem.
👍️0
Sierra20 Sierra20 3 weeks ago
Oh no!!!!!
👍️0
Sierra20 Sierra20 3 weeks ago
CRL? Delayed? What’s going on?
👍️0
Monksdream Monksdream 3 weeks ago
ARQT under$10
👍️0
52172 52172 3 weeks ago
No one knows shit approval is imminent
👍️0
Sierra20 Sierra20 4 weeks ago
Someone knows something sell off started. 😔
👍️0
Sierra20 Sierra20 4 weeks ago
I hope they didn’t get a CRL. People are selling. Something is going on.
👍️0
52172 52172 4 weeks ago
408k share buy ah’s nothing else needed to say!
👍️0
52172 52172 4 weeks ago
20’s imminent mark this post
👍️0
52172 52172 2 months ago
Load the boat easy money
👍️0
52172 52172 2 months ago
Buy opp!
👍️0
52172 52172 2 months ago
ER coming on the 14th might get a bump then data in july
👍️0
Monksdream Monksdream 3 months ago
ARQT under $10
👍️0
52172 52172 4 months ago
Oh yea!!!???
👍️0
52172 52172 4 months ago
12 tomorrow!
👍️0
Denisk Denisk 4 months ago
Headed much lower
👍️0
Zorro Zorro 4 months ago
https://ih.advfn.com/stock-market/NASDAQ/arcutis-biotherapeutics-ARQT/stock-news/93458845/new-research-reveals-genomic-profile-of-seborrheic
👍️0
52172 52172 5 months ago
Headed much higher
👍️0
52172 52172 5 months ago
Some big buys ah
👍️0
ANTADOG ANTADOG 6 months ago
4,38~~ ANT
👍️0

Your Recent History

NASDAQ
ARQT
Arcutis Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved